Recursion Pharmaceuticals (RXRX) held about $557 million in cash at the end of its second quarter of 2026. Investors should ...

Recursion’s August business update highlighted that Genentech opted its first neuroscience target into an early discovery ...

Tempus AI Inc. stocks have been trading up by 6.55 percent after bullish coverage on its AI-driven healthcare data platform.

Its regular expression engine was so good that other languages copied it, and its pragmatic philosophy of making easy things easy and hard things possible influenced Python, Ruby, and PHP. CPAN, its ...

When I set the dial by my ear to '1', I heard the sound of small gears meshing inside the helmet. The green circuit board visible through the small window flickered with a short electronic beep.

Richard Socher, co-founder and CEO of Recursive, argues on the Peter Diamandis podcast that while weak forms of recursive self-improvement ...

A fact I recently learnedI recently finished reading a book on automata, and according to that book, Turing machines, lambda calculus, and recursive functions all have the same computational ...

I am an advocate for AI and the vast possibilities for advancement it can bring across the world. Yet, these advancements ...

Discover the best programming books in 2026 for software engineering, algorithms, system design, interviews, refactoring, and ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...